Edition:
United Kingdom

Evolent Health Inc (EVH.N)

EVH.N on New York Stock Exchange

22.80USD
17 Jul 2018
Change (% chg)

$0.20 (+0.88%)
Prev Close
$22.60
Open
$22.70
Day's High
$23.35
Day's Low
$22.65
Volume
62,204
Avg. Vol
135,818
52-wk High
$27.15
52-wk Low
$10.30

Latest Key Developments (Source: Significant Developments)

Evolent Health Sees Adjusted Services Revenue Growth In Mid-To-High Teens For 2018‍​
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Evolent Health Inc ::EVOLENT HEALTH SAYS ANTICIPATES MEETING OR EXCEEDING ISSUED ADJUSTED REVENUE, ADJUSTED EBITDA GUIDANCE FOR THREE MONTHS ENDED DEC 31, 2017 - SEC FILING.EVOLENT HEALTH SEES ADJUSTED SERVICES REVENUE GROWTH IN MID-TO-HIGH TEENS FOR 2018‍​.EVOLENT HEALTH - ANTICIPATE TRUE HEALTH NEW MEXICO ADJUSTED PREMIUM REVENUE OF ABOUT $95 MILLION-$100 MILLION IN 2018.EVOLENT HEALTH - ANTICIPATE ADJUSTED INTER-COMPANY REVENUES OF ABOUT $20 MILLION IN 2018.  Full Article

Evolent Health And Premier Health Terminate Agreement For Acquisition Of Premier Health Plan
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Evolent Health Inc ::EVOLENT HEALTH AND PREMIER HEALTH ANNOUNCE TERMINATION OF AGREEMENT FOR ACQUISITION OF PREMIER HEALTH PLAN.EVOLENT HEALTH AND PREMIER HEALTH ANNOUNCE TERMINATION OF AGREEMENT FOR ACQUISITION OF PREMIER HEALTH PLAN.- TWO PARTIES WERE UNABLE TO REACH TERMS ON RELATED PARTY AGREEMENTS..‍PREMIER CONTINUES TO EXPLORE STRATEGIC OPTIONS FOR ITS HEALTH PLAN BUSINESS​.EVOLENT HEALTH -CO TO CONTINUE TO PROVIDE SUPPORT SERVICES WITH EXISTING ADMINISTRATIVE AGREEMENT FOR EMPLOYEE SELF-INSURED, MEDICARE ADVANTAGE.  Full Article

Evolent Health announces third quarter 2017 results
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Evolent Health Inc :Evolent Health announces third quarter 2017 results.Q3 revenue $107.9 million versus I/B/E/S view $104.5 million.Evolent Health Inc - ‍for three months ended December 31, 2017, adjusted revenue is expected to be in range of $110.0 million to $112.0 million​.Evolent Health Inc qtrly loss per share $0.18​.Evolent Health Inc - ‍for full year 2017, we expect adjusted revenue to be in range of $432.0 million to $434.0 million​.Evolent Health Inc - ‍for full year 2017, adjusted EBITDA to be in range of loss of $3.0 million to loss of $2.0 million.Evolent Health Inc - ‍ for three months ended December 31, 2017, adjusted EBITDA is expected to be in range of $3.0 million to $4.0 million​.FY2017 revenue view $427.2 million -- Thomson Reuters I/B/E/S.Q4 revenue view $108.9 million -- Thomson Reuters I/B/E/S.  Full Article

Pennant Capital Management reports 5.25 percent passive stake in Evolent Health as of December 31, 2016
Tuesday, 14 Feb 2017 

Pennant Capital Management LLC :Pennant Capital Management LLC reports a 5.25 percent passive stake in Evolent Health Inc as of December 31, 2016 -SEC filing.  Full Article

Evolent Health unit enters into amendment to merger deal dated July 12, 2016
Monday, 3 Oct 2016 

Evolent Health Inc : Amendment to definition of "merger consideration" to be cash in amount of $50.3 million,7.42 million shares of co's Class A common stock . Amendment to reflect decrease in amount of additional contingent share consideration payable under certain conditions to $12.38 million . On Oct 3, co, unit entered into amendment to merger deal dated July 12, 2016 by and among co, Valence Health, Inc - SEC filing .After giving effect to amendment, aggregate amount of merger consideration to be paid by the co at closing is $219.4 million.  Full Article

Evolent Health Q2 adj shr loss $0.12
Thursday, 4 Aug 2016 

Evolent Health Inc : Evolent health announces second quarter 2016 results . Q2 adjusted loss per share $0.12 . Q2 revenue $56.5 million versus i/b/e/s view $52.1 million . Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S .Qtrly loss per share $0.20.  Full Article

Evolent health files for common stock offering
Thursday, 28 Jul 2016 

Evolent Health Inc :Evolent Health Inc Files For Common Stock Offering Of Up To 44.0 Mln Shares Of Class A Common Stock - Sec Filing.  Full Article

BRIEF-Evolent Health Reports Qtrly Loss Per Share $0.18

* Q1 REVENUE $139.7 MILLION VERSUS I/B/E/S VIEW $140.7 MILLION